New Zealand's Medicines Control issues one controlled drug import licence per consignment, works to a processing window of up to 30 working days, and charges $194.22 including GST. That is the straightforward part of the file.
Exporting cannabis to New Zealand runs on two approvals that move in parallel. Your buyer needs a medicinal cannabis licence and then a licence to import a controlled drug. Your product needs to be verified by the Medicinal Cannabis Agency as meeting the minimum quality standard before it can be supplied to New Zealand patients. Health Canada issues your export permit only once that import licence exists.
Most Canadian Licensed Producers assume the permits are the hard part. They are not. The quality standard is where deals stall, and it stalls them for months.
What New Zealand requires before your cannabis can be imported
Start with who owns what. Your buyer owns the licences. You own the evidence that the product qualifies, and that half cannot be handed to a distributor.
Medicinal cannabis products other than CBD products are controlled drugs under the Misuse of Drugs Act 1975. Your New Zealand partner has to hold a medicinal cannabis licence with the right activity before they can apply to Medicines Control for an import licence, and that licence covers a single consignment.
The product side is where a Canadian supplier carries the weight. Before a cannabis-based ingredient or a medicinal cannabis product can be supplied inside New Zealand, someone has to give the Medicinal Cannabis Agency evidence that it meets the minimum quality standard. Once the Agency verifies it, the product is added to the importer's licence and can be sold.
Scope is the part buyers and suppliers most often read differently:
- Starting material does not need to meet the minimum quality standard, either on import or for domestic supply.
- Cannabis-based ingredients and finished medicinal cannabis products do, at both points.
- Product held for export only can sit on a New Zealand supply licence without that verification, provided it was manufactured under GMP and the destination country accepts it.
Dried flower dispensed to a New Zealand patient on prescription is a medicinal cannabis product. If your buyer is describing pharmacy supply, the standard applies to your batch, and your dossier is what proves it. No importer can paper over a testing gap for you.
Inside the minimum quality standard
The standard sits in Part 1 of the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, and its testing limits are built on the European Pharmacopoeia 11th edition. A panel designed around Canadian mandatory testing will come up short, which is why we treat this as a dossier build rather than a COA reprint. Our comparison of export testing requirements across four markets covers the same gap from the buyer's side.
Depending on the product, testing with maximum limits can cover microbial contamination, heavy metals, pesticides, absence of aflatoxins, ochratoxin A, foreign matter, loss on drying, total ash, and residual solvents.
Assay limits are a consistency test
THC and THCA, CBD and CBDA, and any other cannabis-derived ingredient whose stated content is at least one percent, count as active ingredients. For a dried product, each active must assay at no less than 80 percent and no more than 120 percent of its stated content. Dosage products get a tighter window of 90 to 110 percent.
Read that as a batch consistency requirement, not a labelling formality. A cultivar that swings four points of THC between rooms will eventually fall outside a printed claim, and the printed claim is what the Agency assessed.
Shelf life has to be earned
Stability testing follows ICH Q1A(R2), and the product has to stay compliant for microbiological contamination, loss on drying, assay limits, and form across its entire shelf life. Six months of data supports a six-month shelf life. You can file for longer and supply the data later, but the product will not be verified until the Agency has it. We walk through the same logic in our guide to cannabis stability and shelf-life testing.
Packaging, labelling and decontamination
Container materials have to come from European Pharmacopoeia chapters 3.1 and 3.2, the United States Pharmacopeia chapters 660, 661.1 and 661.2, or the EMA guideline on plastic immediate packaging materials. Labelling follows Part 4 of the Medicines Regulations 1984, with the words MEDICINAL CANNABIS PRODUCT on the principal display panel and, for dried product, CONTROLLED DRUG followed by the Class C1 designation. Decontamination must not adversely affect quality and must not use or contain ethylene oxide, a constraint worth reading alongside irradiation standards for export flower. Product must not be in a form intended for smoking, and dried product for domestic supply must be identified as cannabis by microscopic and macroscopic examination.
Pesticides are the quiet failure point. Regulation 18 sets which pesticide active ingredients may be used on a medicinal cannabis crop, and Regulation 7 sets what must be tested and the limits that apply. That means a cultivation programme built on a Canadian input list can disqualify a batch long before anyone opens the certificate of analysis. Fix the crop protection plan first, then talk about shipping.
The GMP gap that stops most Canadian LPs
One requirement reshapes the whole supply plan. Laboratories or manufacturers performing critical tests must be certified compliant with the New Zealand Code of Good Manufacturing Practice. Where that testing happens outside New Zealand, the site has to be certified by an authority that Medsafe recognises, and the recognised list lives in Part 4 of the Guideline on the Therapeutic Products in New Zealand.
Two tests are treated as critical: the assay limits for active ingredients, and form and dosage form. Everything else can run at a GMP-certified site or at an ISO/IEC 17025:2017 accredited laboratory, and that accreditation only counts if the accreditation body signed the ILAC Mutual Recognition Arrangement.
| Test | Who may perform it | What it means for a Canadian LP |
|---|---|---|
| Assay of active ingredients | GMP-certified only | Your potency number needs a GMP site behind it |
| Form and dosage form | GMP-certified only | Applies to dosage products, not dried flower |
| Microbial, heavy metals, pesticides | GMP or ISO 17025 | Existing Canadian panels usually transfer |
| Aflatoxins, ochratoxin A, residual solvents | GMP or ISO 17025 | Often needs adding to a domestic panel |
| Loss on drying, total ash, foreign matter | GMP or ISO 17025 | Pharmacopoeial methods, not Canadian defaults |
Look at the first row again if your quality file rests on an ISO 17025 potency certificate. Potency is the assay. The assay is critical. An ISO-accredited laboratory cannot carry it for a product assessment, no matter how good the instrument.
The physical attributes a buyer inspects on arrival are a separate conversation, covered in our guide to export-grade cannabis flower.
This is where a Health Canada licence stops being sufficient on its own. Good Production Practices govern how you produce under the Cannabis Act, and they are not a GMP certification. Producers who already hold EU-GMP certification from a European competent authority are in a far better position, because that certificate is the thing Medsafe's recognised-authority list is designed to accept. Check the list before you assume yours travels.
A Licensed Producer without an existing GMP certification should not be building a New Zealand revenue forecast this year. Get the certificate, then get the meeting. Method validation follows the same rule: Regulation 9 requires routine quality-control methods to be validated by a GMP-certified manufacturer or laboratory, and identification of active ingredients run at an ISO 17025 laboratory needs validation in line with ICH Q2(R1).
New Zealand has loosened its rules for export-only product, which can sit on a supply licence without minimum quality standard verification when it is GMP-manufactured and the receiving country accepts it. None of that relaxation reaches product coming in for New Zealand patients. The domestic gate stayed exactly where it was.
The New Zealand import path: four gates
Sequence the work in four gates, in this order, and the timeline stops surprising people.
- Gate 1, importer licensing. Your buyer holds a medicinal cannabis licence with a supply activity. Without it, nothing downstream can be applied for.
- Gate 2, product assessment. The Medicinal Cannabis Agency verifies the product against the minimum quality standard using results from representative samples of at least three pilot-scale batches, each at least 10 percent of a production-scale batch. This is the long pole, and it is a one-time build per product.
- Gate 3, import licence. Medicines Control issues the licence to import a controlled drug for that consignment. Budget up to 30 working days, $194.22 including GST, and remember one licence covers up to four preparations or products.
- Gate 4, Canadian export permit. Your Canadian export permit is granted against that New Zealand import licence, the sequence we set out in our guide to the two-permit chain.
Gates 3 and 4 repeat on every shipment. Gate 2 does not, which is why the first order into New Zealand looks nothing like the second one on your operations calendar.
The friction that catches experienced teams is smaller than any of that. The consignment has to be described consistently across every licence application, and discrepancies have to be resolved before a licence issues. A product name written one way on the import application and another way on the export permit is enough to add weeks. Lock the wording in your specification, then copy it everywhere.
AlphaLeaf is a Montreal-based Health Canada Licensed Producer growing indoor, hand-trimmed flower from refined genetics. We hold export authorisation under the Cannabis Act and maintain the ISO 17025 batch data, stability records, and certification documentation that a New Zealand importer needs to put a product assessment in front of the Medicinal Cannabis Agency.
If you are scoping a New Zealand programme and want to know whether a batch profile can hold an 80 to 120 percent assay claim across its shelf life, talk to our export team. Bring your cultivar data and your stability file.
The market is small and specific. The documentation is not optional. Start with the assay.
Frequently Asked Questions
Do Canadian cannabis exports to New Zealand require EU-GMP certification?
Not EU-GMP specifically. New Zealand requires critical tests and manufacture to be covered by GMP certification issued by an authority Medsafe recognises, and EU-GMP from a European competent authority is one of the routes that qualifies. A Health Canada cannabis licence issued under Good Production Practices does not meet that requirement on its own.
How long does a New Zealand cannabis import licence take?
Plan on a 30 working day window at Medicines Control, at a fee of $194.22 including GST. The licence is consignment-specific, so a repeat order needs a fresh application, and a single shipment can carry as many as four preparations.
Does dried cannabis flower have to meet the minimum quality standard?
Yes, when it is imported or supplied within New Zealand as a medicinal cannabis product. Starting material is exempt, and product manufactured in New Zealand for export only can be listed without verification if it is GMP-manufactured and the importing country accepts it.
What are the assay limits for dried cannabis in New Zealand?
Dried product has to land inside a 80 to 120 percent window against its stated content, measured for every active ingredient. Dosage forms are tighter at 90 to 110 percent. Actives here mean THC, THCA, CBD, CBDA, and anything else from the plant declared at one percent or above.
How many batches does the Medicinal Cannabis Agency need for verification?
Three batches, tested on representative samples, is the floor. Each of those batches has to run at 10 percent or more of your normal production-scale batch size, so a single trial run will not satisfy the file.
Can irradiated cannabis be supplied in New Zealand?
The minimum quality standard requires that decontamination treatment does not adversely affect the quality of the product and does not use or contain ethylene oxide. Other decontamination methods are assessed on whether quality holds, so the terpene and microbial data from the treated batch is what the file turns on.
